Physician profile
Amy Amick
NPI 1790975829
$6,331.51
in general payments reported to CMS, 2019-2025
47 companies · $34.40 in 2025
The $34.40 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,372 · 2020: $267 · 2021: $854 · 2022: $2,746 · 2023: $1,058 · 2025: $34.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,092.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,180.27 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Biogen, INC. | $860.94 | 2019-2023 | Vumerity, Tysabri |
| Novartis Pharmaceuticals Corporation | $381.76 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $379.84 | 2019-2023 | Austedo Xr |
| Celgene Corporation | $336.68 | 2021-2023 | Zeposia |
| Genzyme Corporation | $235.71 | 2019-2023 | |
| Allergan, INC. | $222.44 | 2019-2022 | |
| Lilly USA, LLC | $195.72 | 2019-2023 | Amyvid, Emgality, Reyvow |
| Amgen INC. | $178.02 | 2019-2023 | Aimovig |
| Sk Life Science, INC. | $175.61 | 2021-2023 | |
| Acorda Therapeutics, INC | $138.73 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $111.85 | 2019-2022 | |
| Pfizer INC. | $110.11 | 2023 | |
| Ucb, INC. | $108.18 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $102.58 | 2019-2020 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Amick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.